1d agoGuruFocusBEARISH 34Earnings
Archived explainer. For the current picture see today's ANAB page.
Why Is ANAPTYSBIO INC (ANAB) Stock Down Today?
By the Top Tier Newswire AI Desk · November 13, 2026 at 9:50 AM ET · reviewed against 4 wire stories
ANAPTYSBIO INC (ANAB) is down -6.11% in the latest session. Our newswire has captured 4 stories on ANAB across 4 sources in the last 36 hours, with AI sentiment reading bearish (avg 35/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AnaptysBio (ANAB) shares fell 6.11% to $44.85, driven by a quarterly earnings report that missed consensus estimates on both revenue and earnings per share. The company disclosed that first-quarter revenue declined 60.3% year over year to $30.27 million, falling short of analyst expectations by $3.19 million.
What Happened
AnaptysBio filed a Form 8-K on November 12, 2026, to report its fiscal first-quarter 2027 financial results. The company reported GAAP earnings per share of $0.11, which missed the consensus estimate of $0.39 by $0.28. Revenue of $30.27 million also came in below the $33.186 million estimate. The stock had been relatively stable over the previous eight sessions, moving just 0.1% from $47.73 to $47.77, before the gap-down opening.
What The Data Shows
The stock opened at $45.01, a 5.8% gap down from the prior close of $47.77. Intraday trading saw a session high of $46.51 at 8:25 AM ET and a session low of $44.64 at 9:45 AM ET. Volume so far stands at 0.0M shares, which is 0.1 times the three-month daily average. Fundamentally, the company has a market capitalization of $1.5 billion and a P/E ratio of 5.1. Trailing twelve-month revenue has grown 107.7%, and the net margin is 247.0%. The stock has a beta of 0.37 and a 52-week range of $32.90 to $73.30. On November 13, 2026, the stock printed three fresh 52-week lows. Recent insider activity includes a sale by director Renton Hollings on October 1, 2026. Over the last 90 days, there have been zero buys and one sell totaling $249,000.
What To Watch
AnaptysBio has announced participation in upcoming investor conferences. The stock's recent deterioration in sentiment, with a seven-day average lower than the 30-day average, suggests continued volatility as the market digests the earnings miss and litigation challenges.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ANAB by the numbers
Last: $44.85Session: -6.11%7 sessions: -2.65%Coverage: 4 stories / 4 sourcesAI sentiment: 35/100 (bearish)Mkt cap: $1.5BP/E: 5.152w: $32.90 to $73.30
The headlines behind the move
1d agoSeeking AlphaBEARISH 34Earnings
AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19M
AnaptysBio Q1 GAAP EPS is $0.11, missing estimates by $0.28; revenue falls 60.3% year over year to $30.27M, $3.19M below estimates.
1d agoThe FlyBEARISH 22Earnings
AnaptysBio reports Q1 EPS 11c, consensus 39c
1d agoSEC 8-KNEUTRAL 50General
ANAPTYSBIO, INC (ANAB) files 8-K: Items 2.02, 9.01
Filed: 2026-11-12 AccNo: 0001193125-26-458461 Size: 423 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ANAB: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ANAB move explainers: 2026-11-13 · 2026-09-22